Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis
William G. Herrington(Oxford Health NHS Foundation Trust), Natalie Staplin(University of Oxford), Martina Brueckmann, Jennifer B. Green, Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Dominik Steubl(Boehringer Ingelheim (Germany)), Javed Butler(Saint Luke's Health System), Martin Landray(Gentofte Hospital), Alistair Roddick, Sibylle J. Hauske(Heidelberg University), Richard Haynes, Stefan D. Anker(German Centre for Cardiovascular Research), Christoph Wanner(University of Würzburg), Faiez Zannad(Centre Hospitalier Régional et Universitaire de Nancy), Parminder K. Judge(University of Oxford), Rebecca J. Sardell(University of Miami), Milton Packer(Dana-Farber/Harvard Cancer Center)
Cited by 12
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k